Fundraising Fox
Catalera BioSolutions
1 known investors
Find your way into Catalera BioSolutions
Sign up to see every warm intro you have to Catalera BioSolutions
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Catalera BioSolutions team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Catalera develops biopesticide solutions using patented formulation technology for biological active ingredients. The company offers fungicides, insecticides, and miticides registered for use across consumer, professional, and agricultural applications in the United States.
Founders & leadership
KM
Karn ManhasFounderKarn Manhas holds a J.D. from the University of British Columbia and a B.Sc. in Biology and Biotechnology from McGill University, and has over 15 years of experience in leadership roles spanning government, project management, and business development, including service as a Member of the Legislative Assembly in British Columbia and founding multiple biotech companies.
Investors · 1
Funding
SEC filings, press & company announcements- Undisclosed amountSeries ASep 2024 · 4 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Catalera BioSolutions do?
- Catalera develops biopesticide solutions using patented formulation technology for biological active ingredients. The company offers fungicides, insecticides, and miticides registered for use across consumer, professional, and agricultural applications in the United States.
- Who founded Catalera BioSolutions?
- Catalera BioSolutions was founded by Karn Manhas.
- Who are Catalera BioSolutions's investors?
- Catalera BioSolutions's investors include S2G Investments.